Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
-
New hope for young women battling rare, deadly ovarian cancer
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can better control a rare and aggressive type of ovarian cancer. It aims to help young women with this disease, which currently has a very poor outlook. The main goal is to see if …
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for devastating Women's cancers: experimental combo therapy enters major trial
Disease control Recruiting nowThis international study is testing whether combining two newer drugs (dostarlimab and niraparib) works better than using niraparib alone or standard chemotherapy for women with rare, aggressive uterine or ovarian carcinosarcoma that has returned after initial treatment. The tria…
Phase: PHASE2, PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New chemo strategy tested for ovarian cancer when standard treatment falters
Disease control Recruiting nowThis study is for people with advanced ovarian cancer where the first few rounds of standard chemotherapy didn't shrink the tumor enough and surgery to remove all the cancer wasn't possible. It will test if switching to a more frequent, 'dose-dense' chemotherapy schedule is bette…
Phase: PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC